Drug Delivery Market Size, Share, Opportunities, And Trends By Type (Inhalation Drug Delivery, Injectable Drug Delivery, Nasal Drug Delivery, Oral Drug Delivery, Transdermal Drug Delivery), By Technique (Needle-Free Injectors, Drug Delivery Patches, Autoinjectors, Others), By Application (Cancer Treatment, Infectious Diseases Treatment, Others), And By Geography - Forecasts From 2024 To 2029

The drug delivery market was valued at US$835.217 billion in 2022 and is expected to grow at a CAGR of 8.90% over the forecast period to reach a total market size of US$1,516.944 billion by 2029.

A drug delivery device is a specialized device for the controlled and targeted release of drugs. Drugs have been extending health benefits and lifespans for centuries, and the way medicines are delivered has changed over the last few decades. Molecular biology strategies can be used to discover a medication that has acceptable side effects due to interacting with parts of the body that are not targeted by the drug. Systems for delivering drugs control how much of the drug is released and how far it reaches the target.

Increasing incidences of chronic diseases, growth in the medical diagnostics market, advancements in technology, and new company launches are driving the market growth. Globally, chronic disease prevalence is expected to rise by 57% by 2020, according to the World Health Organization.

Additionally, several pharmaceutical companies are suddenly experiencing a surge in demand for drugs designed to treat infectious diseases because of the Coronavirus outbreak globally, which has been a major factor boosting the drug delivery demand. 

The growing awareness surrounding pharmaceutical drug delivery systems is also contributing to the market growth. Furthermore, the pharmaceutical drug delivery market growth is being influenced by additional factors such as an increase in healthcare and government funding. In addition, the emergence of various chronic diseases, which necessitate the use of pharmaceutical delivery systems, is a key driver of the pharmaceutical delivery systems market. The drug delivery market is, however, hindered by the increasing number of drug recalls and failures.

Additionally, the forecast period should see lucrative opportunities in developing economies due to their high growth potential. A great number of drugs and vaccines are undergoing various clinical trials and are expected to be made available to patients in the coming months and years under guidelines for emergency usage authorizations for COVID-19 treatment. Vaccines are being developed, manufactured, and administered at a mass level, which is resulting in high demand for different drug delivery systems over the forecast period. 

Market Drivers:

• Growth in the biologics drug demand is anticipated to surge the drug delivery market.

Biologic drugs are the most advanced treatments available for a variety of illnesses and conditions. Approximately 41 million people die each year from chronic diseases, according to World Health Organization statistics, and about 17.9 million people die from cardiovascular disease, followed by cancer (9 million), respiratory diseases - 3.9 million, and diabetes - 1.6 million. Furthermore, approximately 80% of chronic disease deaths result from these four groups. The increasing number of geriatrics also means that chronic diseases will affect more people, thus increasing the demand for biologics. The number of people over the age of 65 will rise from one in 11 in 2019 to one in six by 2050 (16%), up from one in 11 at the beginning of this year (9%) (Source: WHO). Investors have also been driving the overall market growth.

Moreover, in Singapore, Novartis AG invested USD 700 million in the establishment of a biologics center, while Bristol-Myers Squibb spent more than USD 900 million on a large biologic facility in Ireland, which opened in 2019. In the coming years, due to the significant growth in the biologics market and the fact that generic injectables are mainly administered via injection, the injectable drug delivery market should witness further growth. 

Market Restraint:

• Injuries caused by needlesticks could hamper the drug delivery market growth.

One of the major risks associated with injectable drug delivery is needlestick injuries. According to Pharma Jet, 600,000-800,000 needlestick injuries are reported in the United States every year. The Occupational Safety and Health Administration (OSHA) estimates that 5.6 million workers in the US are at risk of being exposed to blood-borne pathogens because of needlestick injuries. In addition, the CDC estimates that US hospitals suffer 385,000 needlestick injuries annually. 

In addition, the WHO found that 34.7% of cases of Hepatitis B, 56.9% of cases of Hepatitis C, and 46.7% of cases of HIV/AIDS among healthcare workers worldwide were associated with injuries caused by needlesticks.

Key Developments:

• February 2023- Innovation Zed, an Irish R&D company, secured a CE Mark for the InsulCheck DOSE add-on device, which automatically logs the time and dialled doses for insulin pen users. The discreet device captures dose value, injection event time stamp, temperature, and mounting and unmounting events and sends real-time data to a compatible display device. It features a vibrant OLED screen for increased user engagement and was developed in collaboration with SHL Medical and SHL Technologies to address compatibility challenges in injection pen designs.
• January 2023- Biocorp, a France-based company, received FDA clearance for SoloSmart®, Sanofi's smart cap for disposable insulin pens. This marks the second FDA clearance for Biocorp's Mallya platform. SoloSmart connects SoloStar® insulin pens, automatically recording key treatment information and transmitting it to a digital application. It provides healthcare professionals with an easy way to follow patients during multitherapy treatments. The FDA's authorization reinforces Biocorp's technological leadership in the smart pens market. SoloSmart is available for sale from 2020 and is part of Biocorp's connected solutions portfolio.
• September 2022- BD introduced a next-generation glass pre-fillable syringe (PFS) for vaccine manufacturing, designed for reliability and efficiency. The BD EffivaxTM Glass Prefillable Syringe, developed in collaboration with pharmaceutical companies, is designed to meet the complex needs of vaccine manufacturing. With 70% of the top 100 biopharmaceutical companies relying on BD for PFS supply, the new design enhances fill/finish and container reliability, reducing line stoppage risk and improving total cost of ownership, manufacturing capacity, and supply availability. BD is benefited from a $1.2 billion investment to expand and upgrade manufacturing capacity and technology for PFS.
• September 2022- Corium, a biopharmaceutical company, published phase 1 results for ADLARITY, a once-weekly transdermal system for Alzheimer's dementia patients. The study found that ADLARITY delivered drug exposure equivalent to oral donepezil, with lower gastrointestinal adverse events. The FDA approved ADLARITY in 5 or 10 mg/day formulations, making it the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. The trial supports ADLARITY as a compliant and safe once-weekly dosing regimen for Alzheimer's dementia treatment.
• June 2022- Novartis was acquired Kedalion Therapeutics and its AcuStream™ platform, a topical ocular delivery device designed for precise dosing and delivery of certain topical ophthalmic medications. The preservative-free, electromechanical device may improve patient experience and facilitate precise dosing. Novartis plans to develop AcuStream technology for use with existing and future front-of-eye therapies, including Xiidra®, a first-in-class prescription LFA 1 antagonist for dry eye disease treatment. Kedalion Therapeutics completed its Series B financing led by Novartis, with an exclusive option to acquire the company and its AcuStream technology.

Drug Delivery Market Scope: 

Market Segmentation:

• By Type
  • Inhalation Drug Delivery
  • Injectable Drug Delivery
  • Nasal Drug Delivery
  • Oral Drug Delivery
  • Transdermal Drug Delivery 
• By Technique
  • Needle-free injectors
  • Drug delivery patches
  • Autoinjectors
  • Others
• By Application
  • Cancer treatment
  • Infectious diseases treatment
  • Others
• BY Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Japan
    • Others